- Home
- SHFS vs KPRX Comparison
SHFS vs KPRX Comparison
Compare SHFS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- KPRX
- Stock Information
- Founded
- SHFS 2015
- KPRX 1998
- Country
- SHFS United States
- KPRX United States
- Employees
- SHFS N/A
- KPRX N/A
- Industry
- SHFS Finance: Consumer Services
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SHFS Finance
- KPRX Health Care
- Exchange
- SHFS Nasdaq
- KPRX Nasdaq
- Market Cap
- SHFS 9.5M
- KPRX 9.2M
- IPO Year
- SHFS N/A
- KPRX N/A
- Fundamental
- Price
- SHFS $2.74
- KPRX $2.53
- Analyst Decision
- SHFS
- KPRX Strong Buy
- Analyst Count
- SHFS 0
- KPRX 1
- Target Price
- SHFS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SHFS 76.8K
- KPRX 48.4K
- Earning Date
- SHFS 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- SHFS N/A
- KPRX N/A
- EPS Growth
- SHFS N/A
- KPRX N/A
- EPS
- SHFS N/A
- KPRX N/A
- Revenue
- SHFS $11,720,493.00
- KPRX N/A
- Revenue This Year
- SHFS N/A
- KPRX N/A
- Revenue Next Year
- SHFS N/A
- KPRX N/A
- P/E Ratio
- SHFS N/A
- KPRX N/A
- Revenue Growth
- SHFS N/A
- KPRX N/A
- 52 Week Low
- SHFS $1.84
- KPRX $2.21
- 52 Week High
- SHFS $10.53
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SHFS 36.04
- KPRX 45.20
- Support Level
- SHFS $2.77
- KPRX $2.21
- Resistance Level
- SHFS $3.52
- KPRX $2.68
- Average True Range (ATR)
- SHFS 0.40
- KPRX 0.16
- MACD
- SHFS -0.19
- KPRX -0.02
- Stochastic Oscillator
- SHFS 6.38
- KPRX 50.00
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.